Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases
- PMID: 24494707
- DOI: 10.3111/13696998.2014.890937
Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases
Abstract
Background: Patients with bone metastases secondary to breast cancer are pre-disposed to skeletal-related events (SREs), including spinal cord compression (SCC), pathologic fracture (PF), surgery to bone (SB), and radiotherapy to bone (RT).
Objective: To document current patterns of healthcare utilization and costs of SREs in patients with breast cancer and bone metastases.
Methods: This was a retrospective, observational study using the Thomson MedStat MarketScan Commercial Claims and Encounters database from 9/2002 to 6/2011. Study subjects included all persons with claims for breast cancer and for bone metastases, and ≥1 claims for an SRE. Unique SRE episodes were identified based on a gap of at least 90 days without an SRE claim, and classified by treatment setting (inpatient or outpatient) and SRE type (SCC, PF, SB, or RT).
Results: Of 17,266 patients with breast cancer and bone metastases, 9142 (53%) had one or more SRE episodes. Among 5809 patients who met all other criteria, there were 7617 SRE episodes over mean (SD) follow-up of 17.2 (15.2) months. The percentage of episodes that required inpatient treatment ranged from 11% (RT) to 76% (SB). On average, inpatient SCC episodes (n=83 episodes) were most costly; while outpatient PF episodes (n=552 episodes) were least costly. Of the total SRE costs (mean [SE] $21,072 [$36,462]/episode), 36% were attributable to outpatient RT (n=5265 episodes) and 31% to inpatient PF (n=838 episodes).
Limitations: The administrative claims data used in this study may lack sensitivity and specificity for identification of clinical events and may not be generalizable to other populations. Also, for some SRE episode categories, the number of events was small and cost estimates may lack precision.
Conclusion: In patients with breast cancer and bone metastases, SREs are associated with high costs and hospitalizations.
Similar articles
-
Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases.Prostate Cancer Prostatic Dis. 2013 Mar;16(1):23-7. doi: 10.1038/pcan.2012.42. Epub 2012 Nov 13. Prostate Cancer Prostatic Dis. 2013. PMID: 23146970
-
The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium.J Med Econ. 2013;16(4):539-46. doi: 10.3111/13696998.2013.774279. Epub 2013 Feb 21. J Med Econ. 2013. PMID: 23425250
-
The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer.Oncology. 2004;67(5-6):390-6. doi: 10.1159/000082923. Oncology. 2004. PMID: 15713995
-
Clinical, economic and humanistic burdens of skeletal-related events associated with bone metastases.Expert Rev Pharmacoecon Outcomes Res. 2013 Aug;13(4):483-96. doi: 10.1586/14737167.2013.820959. Epub 2013 Jul 18. Expert Rev Pharmacoecon Outcomes Res. 2013. PMID: 23862654 Review.
-
Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer.Curr Opin Oncol. 2014 May;26(3):274-83. doi: 10.1097/CCO.0000000000000071. Curr Opin Oncol. 2014. PMID: 24626126 Review.
Cited by
-
Assessment of Bone Health Awareness and Education in Breast Cancer Patients with Bone Metastasis in the USA.J Cancer Educ. 2023 Oct;38(5):1522-1530. doi: 10.1007/s13187-023-02293-w. Epub 2023 Apr 28. J Cancer Educ. 2023. PMID: 37118404 Free PMC article.
-
Validation of Algorithms to Identify Bone Metastases Using Administrative Claims Data in a Japanese Hospital.Drugs Real World Outcomes. 2023 Jun;10(2):187-194. doi: 10.1007/s40801-022-00347-x. Epub 2023 Jan 18. Drugs Real World Outcomes. 2023. PMID: 36652116 Free PMC article.
-
COSTS ANALYSIS OF SPINAL COLUMN METASTASES SURGICAL TREATMENT.Acta Ortop Bras. 2022 Dec 2;30(spe2):e251579. doi: 10.1590/1413-785220223002e251579. eCollection 2022. Acta Ortop Bras. 2022. PMID: 36506865 Free PMC article.
-
Inflammatory conversion of quiescent osteoblasts by metastatic breast cancer cells through pERK1/2 aggravates cancer-induced bone destruction.Bone Res. 2021 Sep 29;9(1):43. doi: 10.1038/s41413-021-00158-w. Bone Res. 2021. PMID: 34588427 Free PMC article.
-
Progress in Targeted Alpha-Particle-Emitting Radiopharmaceuticals as Treatments for Prostate Cancer Patients with Bone Metastases.Molecules. 2021 Apr 9;26(8):2162. doi: 10.3390/molecules26082162. Molecules. 2021. PMID: 33918705 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous